Trial Profile
Brazil Xience V Everolimus-Eluting Coronary Stent System "Real-World" Outcomes Registry.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Dec 2012
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms BRAVO
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Oct 2009 New trial record